

# Laura Gramantieri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4879285/laura-gramantieri-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101 papers	7,112 citations	39 h-index	83 g-index
106 ext. papers	7,794 ext. citations	6.4 avg, IF	5.16 L-index

#	Paper	IF	Citations
101	Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma <b>2022</b> , 301-315		
100	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. <i>Cells</i> , <b>2021</b> , 10,	7.9	3
99	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 369-385	5.3	9
98	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. <i>OncoTargets and Therapy</i> , <b>2021</b> , 14, 4305-4308	4.4	
97	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 741-757	5.3	7
96	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
95	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4485-4493	12.9	9
94	MiR-30e-3p Influences Tumor Phenotype through / Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2020</b> , 80, 1720-1734	10.1	27
93	Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1159-1169	13.4	17
92	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2020</b> , 15, 773-785	5	8
91	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
90	Role of SIRT-3, p-mTOR and HIF-1 $\alpha$ in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
89	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	26
88	Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. <i>Oncogene</i> , <b>2019</b> , 38, 7035-7045	9.2	34
87	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 14, 239-250	10.7	9
86	Brivanib in combination with Notch3 silencing shows potent activity in tumour models. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 601-611	8.7	5
85	Animal Models of Hepatocellular Carcinoma Prevention. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6

84	MicroRNAs in Animal Models of HCC. <i>Cancers</i> , <b>2019</b> , 11,	6.6	14
83	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , <b>2018</b> , 120, 95-102	2	16
82	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 4	9.8	48
81	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. <i>Molecular Therapy - Nucleic Acids</i> , <b>2018</b> , 11, 485-493	10.7	59
80	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. <i>Oncotarget</i> , <b>2018</b> , 9, 17895-17905	3.3	5
79	LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , <b>2018</b> , 9, 35085-35099	3.3	31
78	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 15350-15364	3.3	59
77	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3953-3965	12.9	105
76	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 446854.9	4.9	10
75	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2397-2407	4	12
74	The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 891-8	13.4	20
73	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 18,	6.3	27
72	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 31361-71	3.3	33
71	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 39609-39626	3.3	21
70	Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. <i>Oncotarget</i> , <b>2016</b> , 7, 32375-93	3.3	60
69	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	22
68	Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. <i>Hepatology</i> , <b>2015</b> , 61, 249-59	11.2	45
67	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. <i>Cell Death and Differentiation</i> , <b>2015</b> , 22, 46-57	12.7	114

66	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141448	3.7	94
65	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2015</b> , 2, 29-38	5.3	23
64	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. <i>Gastrointestinal Cancer: Targets and Therapy</i> , <b>2015</b> , 89		
63	The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1 $\alpha$ activity by changing miR expression patterns in human cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 239-48	6.1	48
62	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 203-16	6.6	36
61	Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2014</b> , 34, e302-7	7.9	98
60	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2014</b> , 5, 10607-20	3.3	37
59	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. <i>Frontiers in Genetics</i> , <b>2013</b> , 4, 64	4.5	31
58	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 1167-78	4.4	42
57	Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. <i>PLoS ONE</i> , <b>2013</b> , 8, e73964	3.7	45
56	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2013</b> , 4, 1618-31	3.3	40
55	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 48, 391-401	6.8	28
54	CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. <i>American Journal of Pathology</i> , <b>2012</b> , 181, 413-22	5.8	46
53	In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. <i>Journal of Pathology</i> , <b>2012</b> , 227, 275-85	9.4	155
52	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , <b>2012</b> , 56, 1025-33	11.2	132
51	From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6 Suppl 1, 93-8	3.7	20
50	MicroRNA response to environmental mutagens in liver. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2011</b> , 717, 67-76	3.3	22
49	microRNA involvement in hepatocellular carcinoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2011</b> , 11, 500-21	2.2	78

48	Mutated beta-catenin evades a microRNA-dependent regulatory loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 4840-5	11.5	43
47	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2010</b> , 48, 1319-26	5.9	17
46	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. <i>Cancer Research</i> , <b>2010</b> , 70, 5184-93	10.1	347
45	Oncogenic role of miR-483-3p at the IGF2/483 locus. <i>Cancer Research</i> , <b>2010</b> , 70, 3140-9	10.1	239
44	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5073-81	12.9	267
43	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. <i>Cancer Research</i> , <b>2009</b> , 69, 5761-7	10.1	346
42	Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 969-79	13.4	81
41	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. <i>Laboratory Investigation</i> , <b>2008</b> , 88, 995-1007	5.9	15
40	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. <i>Oncogene</i> , <b>2008</b> , 27, 5651-61	9.2	545
39	MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , <b>2008</b> , 12, 2189-204	5.6	212
38	Hepatocellular carcinoma: epidemiology and clinical aspects. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 130-43	16.7	78
37	Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. <i>Liver International</i> , <b>2007</b> , 27, 997-1007	7.9	88
36	Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. <i>Cancer Cell</i> , <b>2007</b> , 12, 215-29	24.3	599
35	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. <i>Cancer Research</i> , <b>2007</b> , 67, 6092-9	10.1	695
34	Notch3 intracellular domain accumulates in HepG2 cell line. <i>Anticancer Research</i> , <b>2006</b> , 26, 2123-7	2.3	28
33	GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. <i>Human Pathology</i> , <b>2005</b> , 36, 1154-62	3.7	25
32	Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 8156-9	10.1	89
31	Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 594-602	3.3	2

30	Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. <i>Journal of Clinical Ultrasound</i> , <b>2003</b> , 31, 387-91	1	12
29	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 997-1003	13.4	37
28	Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. <i>Molecular Diagnosis and Therapy</i> , <b>2003</b> , 7, 201-7		17
27	Multigene Methylation Analysis of Gastrointestinal Tumors. <i>Molecular Diagnosis and Therapy</i> , <b>2003</b> , 7, 201-207		32
26	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. <i>Oncogene</i> , <b>2002</b> , 21, 2564-72	9.2	49
25	Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. <i>Free Radical Research</i> , <b>2002</b> , 36, 939-48	4	80
24	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. <i>Ultrasound in Medicine and Biology</i> , <b>2001</b> , 27, 893-9	3.5	54
23	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. <i>Gut</i> , <b>2001</b> , 48, 251-9	19.2	477
22	Serum xanthine oxidase in human liver disease. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1194-9	0.7	40
21	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. <i>Journal of Medical Virology</i> , <b>2000</b> , 62, 25-8	19.7	13
20	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. <i>Hepatology</i> , <b>2000</b> , 31, 349-57	11.2	33
19	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 306-11	4	3
18	Assessment of vascular patterns of small liver mass lesions: value and limitation of the different Doppler ultrasound modalities. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3537-46	0.7	35
17	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 5445-9	11.5	74
16	Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. <i>Clinical and Experimental Immunology</i> , <b>1999</b> , 115, 515-20	6.2	25
15	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. <i>Hepatology</i> , <b>1999</b> , 30, 58-64	11.2	126
14	Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). <i>Clinica Chimica Acta</i> , <b>1999</b> , 281, 147-58	6.2	19
13	Duplex Doppler findings in splenic arteriovenous fistula. <i>Journal of Clinical Ultrasound</i> , <b>1998</b> , 26, 103-5	1	9

12	Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1998</b> , 12, 475-81	6.1	6
11	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 1925-30	0.7	30
10	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1997</b> , 9, 799-804	2.2	28
9	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 979-85	13.4	215
8	A case of extracranial vertebral artery dissection with spontaneous recovery Diagnosis and follow-up by duplex and color Doppler. <i>European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology</i> , <b>1997</b> , 6, 197-201		
7	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. <i>Ultrasound in Medicine and Biology</i> , <b>1997</b> , 23, 675-82	3.5	49
6	Possible mechanisms for changes of intrasplenic arterial impedance indices in portal hypertension. <i>Hepatology</i> , <b>1997</b> , 26, 513-4	11.2	9
5	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 60-5	13.4	17
4	Alteration of DNA ploidy and cell nuclearity in human hepatocellular carcinoma associated with HBV infection. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 848-53	13.4	7
3	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 800-8	4	8
2	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1996</b> , 11, 1115-20	4	13
1	Diagnostic and prognostic value of DNA ploidy and cell nuclearity in ultrasound-guided liver biopsies. <i>Cancer</i> , <b>1994</b> , 74, 1713-9	6.4	19